In which situations are you comfortable with alternative dosing of ovarian suppression (e.g Lupron q3m) for premenopausal patients during adjuvant breast cancer treatment?

My first option, when feasible/practical is to use every 4-week formulation of GNRH analog ovarian suppression treatment for hormone receptor-positive breast cancer. When that frequency of treatment presents a hardship, I generally feel comfortable with using ovarian suppression using depot GNRH ana...

There is additional data supporting Q3month Goserelin (Wu et al., ESMO Open 2023). In this ESMO study, the E2 suppression rate was 98.96% in patients who received goserelin at 10.8 mg every 3 months compared with 92.71% in those who received a 3.6 mg dose every month (risk difference, 0.065; 95% CI,...